Aberrant TGFβ1 signaling in UCS [26] and other carcinomas of the breast and pancreas endow tumor cells with a selective advantage of enhanced motility and resistance to chemotherapeutics with an expansion of cancer-initiating stem-like cells [27–29]. This evidence concerns the gene TGFB1 and carcinoma.